Market closed
Theravance Biopharma/$TBPH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
99
Website
TBPH Metrics
BasicAdvanced
$472M
Market cap
-
P/E ratio
-$1.01
EPS
0.22
Beta
-
Dividend rate
Price and volume
Market cap
$472M
Beta
0.22
52-week high
$11.71
52-week low
$7.44
Average daily volume
228K
Financial strength
Current ratio
4.97
Quick ratio
4.617
Long term debt to equity
21.968
Total debt to equity
21.968
Interest coverage (TTM)
-15.63%
Management effectiveness
Return on assets (TTM)
-6.41%
Return on equity (TTM)
-22.88%
Valuation
Price to revenue (TTM)
7.414
Price to book
2.54
Price to tangible book (TTM)
2.54
Price to free cash flow (TTM)
-38.073
Growth
Revenue change (TTM)
15.93%
Earnings per share change (TTM)
6.00%
3-year revenue growth (CAGR)
2.26%
3-year earnings per share growth (CAGR)
-33.09%
What the Analysts think about TBPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
TBPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TBPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TBPH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $472M as of December 24, 2024.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of December 24, 2024.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.